BidaskClub upgraded shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) from a sell rating to a hold rating in a report published on Saturday.

Other analysts have also issued research reports about the company. Mizuho set a $34.00 price objective on WAVE Life Sciences and gave the company a buy rating in a research note on Friday, August 18th. Jefferies Group LLC reaffirmed a buy rating and set a $40.00 price objective (down previously from $42.00) on shares of WAVE Life Sciences in a research note on Thursday, August 10th. JMP Securities reaffirmed an outperform rating and set a $40.00 price objective on shares of WAVE Life Sciences in a research note on Friday, June 9th. Zacks Investment Research lowered WAVE Life Sciences from a hold rating to a sell rating in a research note on Thursday, July 27th. Finally, ValuEngine lowered WAVE Life Sciences from a hold rating to a sell rating in a research note on Friday, June 16th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $40.00.

WAVE Life Sciences (NASDAQ WVE) traded up 7.76% during midday trading on Friday, reaching $18.75. 223,906 shares of the company were exchanged. WAVE Life Sciences has a 52 week low of $15.15 and a 52 week high of $40.15. The firm’s 50 day moving average price is $18.16 and its 200-day moving average price is $22.33. The stock’s market capitalization is $520.50 million.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.14. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.73 million. WAVE Life Sciences had a negative net margin of 3,375.12% and a negative return on equity of 55.19%. Equities analysts forecast that WAVE Life Sciences will post ($3.71) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “WAVE Life Sciences Ltd. (WVE) Upgraded to Hold at BidaskClub” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://theolympiareport.com/2017/08/27/wave-life-sciences-ltd-wve-upgraded-to-hold-at-bidaskclub.html.

In other WAVE Life Sciences news, insider Michael A. Panzara sold 7,414 shares of the firm’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $16.67, for a total value of $123,591.38. Following the sale, the insider now directly owns 15,336 shares of the company’s stock, valued at approximately $255,651.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 53.00% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of WVE. Redmile Group LLC raised its stake in shares of WAVE Life Sciences by 75.0% in the second quarter. Redmile Group LLC now owns 2,224,407 shares of the company’s stock worth $41,374,000 after buying an additional 953,310 shares during the last quarter. Clough Capital Partners L P raised its stake in shares of WAVE Life Sciences by 93.3% in the first quarter. Clough Capital Partners L P now owns 408,006 shares of the company’s stock worth $10,935,000 after buying an additional 196,903 shares during the last quarter. Northern Trust Corp raised its stake in shares of WAVE Life Sciences by 66.3% in the second quarter. Northern Trust Corp now owns 165,794 shares of the company’s stock worth $3,085,000 after buying an additional 66,120 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of WAVE Life Sciences by 40.3% in the second quarter. Vanguard Group Inc. now owns 215,691 shares of the company’s stock worth $4,012,000 after buying an additional 61,910 shares during the last quarter. Finally, Eventide Asset Management LLC raised its stake in shares of WAVE Life Sciences by 13.0% in the first quarter. Eventide Asset Management LLC now owns 433,500 shares of the company’s stock worth $11,921,000 after buying an additional 49,870 shares during the last quarter. 57.03% of the stock is currently owned by hedge funds and other institutional investors.

About WAVE Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Analyst Recommendations for WAVE Life Sciences (NASDAQ:WVE)

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.